For cancer patients receiving immunotherapy, why some respond dramatically while others barely at all has long been one of oncology's most frustrating puzzles. Mounting evidence now points to a surprisingly influential variable: the trillions of microorganisms residing in the gut. This convergence of microbiome science and cancer immunology may fundamentally reshape how oncologists personalize treatment.
This review, published in the Chinese Medical Journal, synthesizes current mechanistic and clinical evidence on how gut bacterial communities interact with immune checkpoint blockade (ICB) therapies — drugs like anti-PD-1 and anti-CTLA-4 that unleash T-cell responses against tumors. The analysis identifies specific bacterial species that either amplify or suppress ICB efficacy by modulating immune cell activation, antigen presentation pathways, and systemic inflammatory tone. It further catalogs actionable intervention strategies — including prebiotic supplementation, fecal microbiota transplantation (FMT), and targeted metabolite therapies — as levers to overcome ICB resistance. Notably, the review highlights emerging microbial biomarker signatures in melanoma, non-small cell lung cancer, and hepatobiliary cancers that may predict treatment response before therapy begins, and addresses the gut microbiome's dual role in both driving efficacy and contributing to immune-related colitis, a major ICB toxicity.
This review arrives at a genuinely consequential moment. Several small clinical trials have already demonstrated that FMT from ICB responders can partially restore responsiveness in refractory melanoma patients, lending real-world weight to the mechanistic claims here. The field is moving from correlation to causation, though the review's translational strategies remain aspirational for most clinical settings — FMT protocols lack standardization, and microbial biomarker panels are not yet validated across diverse populations. As a narrative review rather than a meta-analysis, it cannot quantify effect sizes or resolve conflicting findings. Still, the synthesis is clinically orienting and reflects a broader paradigm shift: the gut microbiome is no longer a bystander in cancer care but an active, modifiable determinant of immunotherapy success.